The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life

被引:37
|
作者
Raluy-Callado, Mireia [1 ]
Chen, Wen-Hung [2 ]
Whiteman, David A. H. [3 ]
Fang, Juanzhi [3 ]
Wiklund, Ingela [1 ]
机构
[1] Evidera, London W6 7HA, England
[2] Evidera, Bethesda, MD 20814 USA
[3] Shire HGT, Lexington, MA 02421 USA
来源
关键词
Hunter syndrome; Mucopolysaccharidosis type II; Lysosomal storage disease; Patient-reported outcomes; Health-related quality of life; ENZYME REPLACEMENT THERAPY; NATURAL-HISTORY; CHILDREN; QUESTIONNAIRE; IDURSULFASE; FORM;
D O I
10.1186/1750-1172-8-101
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on health-related quality of life (HRQL). The objective of this study was to describe this impact using the Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire and a range of standard validated questionnaires previously used in paediatric populations. Methods: Clinical and demographic characteristics collected in a clinical trial and responses to four HRQL questionnaires completed both by patients and parents prior to enzyme replacement treatment were used. The association between questionnaire scores and clinical function parameters were tested using Spearman rank-order correlations. Results were compared to scores in other paediatric populations with chronic conditions obtained through a targeted literature search of published studies. Results: Overall, 96 male patients with MPS II and their parents were enrolled in the trial. All parents completed the questionnaires and 53 patients above 12 years old also completed the self-reported versions. Parents' and patients' responses were analysed separately and results were very similar. Dysfunction according to the HS-FOCUS and the CHAQ was most pronounced in the physical function domains. Very low scores were reported in the Self Esteem and Family Cohesion domains in the CHQ and HUI3 disutility values indicated a moderate impact. Scores reported by patients and their parents were consistently lower than scores in the other paediatric populations identified (except the parent-reported Behaviour score); and considerably lower than normative values. Conclusions: This study describes the impact on HRQL in patients with MPS II and provides a broader context by comparing it with that of other chronic paediatric diseases. Physical function and the ability to perform day-to-day activities were the most affected areas and a considerable impact on the psychological aspects of patients' HRQL was also found, with a higher level of impairment across most dimensions (particularly Pain and Self Esteem) than that of other paediatric populations. Such humanistic data provide increasingly important support for establishing priorities for health care spending, and as a component of health economic analysis.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
    Mireia Raluy-Callado
    Wen-Hung Chen
    David A H Whiteman
    Juanzhi Fang
    Ingela Wiklund
    [J]. Orphanet Journal of Rare Diseases, 8
  • [2] Adaptive functioning and health-related quality of life of patients with mucopolysaccharidosis type ii (hunter syndrome)
    Needham, Mary C.
    Packman, Wendy
    Packman, Seymour
    [J]. MOLECULAR GENETICS AND METABOLISM, 2012, 105 (03) : 344 - 344
  • [3] The Impact on Health Related Quality of Life (HRQOL) in Patients with Hunter Syndrome
    Wiklund, Ingela
    Raluy, Mireia
    Jangelind, Yvonne
    Whiteman, David
    Conway, Anne Marie
    Pang, Francis
    Chen, Wen-Hung
    Muenzer, Joseph
    [J]. MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S66 - S66
  • [4] MUCOPOLYSACCHARIDOSIS TYPE-II (HUNTER SYNDROME)
    LAMBOTTE, C
    WINANT, R
    LOEB, H
    TONDEUR, M
    VAMOS, E
    VANHOOF, F
    NEUFELD, E
    [J]. ARCHIVES FRANCAISES DE PEDIATRIE, 1971, 28 (05): : 568 - &
  • [5] Mucopolysaccharidosis Type II, Hunter's Syndrome
    Tylki-Szymanska, Anna
    [J]. PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2014, 12 : 107 - 113
  • [6] The impact of burning mouth syndrome on health-related quality of life
    Souza, Fabricio T. A.
    Santos, Talita P. M.
    Bernardes, Vanessa F.
    Teixeira, Antonio L.
    Kuemmer, Arthur M.
    Silva, Tarcilia A.
    Abreu, Mauro H. N. G.
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2011, 9
  • [7] The impact of irritable bowel syndrome on health-related quality of life
    Gralnek, IM
    Hays, RD
    Kilbourne, A
    Naliboff, B
    Mayer, EA
    [J]. GASTROENTEROLOGY, 2000, 119 (03) : 654 - 660
  • [8] The impact of burning mouth syndrome on health-related quality of life
    Fabrício TA Souza
    Tálita PM Santos
    Vanessa F Bernardes
    Antônio L Teixeira
    Arthur M Kümmer
    Tarcília A Silva
    Mauro HNG Abreu
    [J]. Health and Quality of Life Outcomes, 9
  • [9] Osteoporosis in mucopolysaccharidosis type II (Hunter's syndrome)
    Rigante, D
    Segni, G
    Ricci, R
    Di Stasio, A
    Caradonna, P
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S502 - S502
  • [10] Mucopolysaccharidosis type II (Hunter's syndrome) in Taiwan
    Su, PH
    Hwu, WL
    Chiang, SC
    Chiu, PC
    Lin, SJ
    Shu, SG
    Wang, TR
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1998, 97 (03) : 186 - 190